B
Bioherent provides a diagnostic test that identifies specific drug allergies through advanced immunoassay technology. This test enables healthcare providers to make informed decisions, reducing the risk of adverse drug reactions in patients.
Updated 4 months ago
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Bioherent provides a diagnostic test that identifies specific drug allergies through advanced immunoassay technology. This test enables healthcare providers to make informed decisions, reducing the risk of adverse drug reactions in patients.